GSK Consumer Unit Finds Growth Groove By Innovating, Acquiring, Expanding
This article was originally published in The Rose Sheet
Executive Summary
GlaxoSmithKline's consumer health-care business increased its sales by 8 percent in the firm's latest earnings period, reflecting the firm's "strategy to grow and diversify the business away from a dependency on 'white pill/western markets,'" CEO Andrew Witty noted
You may also be interested in...
GSK Iso-Active Toothpastes Employ Double Foam, Claim Triple Efficacy
GlaxoSmithKline is replacing the conventional toothpaste tube with a canister like those used for shaving products to deliver its new Aquafresh and Sensodyne products with "twice the foam volume as ordinary toothpaste.
Growth Strategy Applied: GSK Oral Care, Consumer Biz. Up In Q2
GlaxoSmithKline's oral-care business thrived in the second quarter of 2009, and CEO Andrew Witty makes it sound simple: "We've innovated our products and we advertise our products at the right level," he said during GSK's July 22 earnings call
GSK Gains Foothold In U.S. Skin Care With Stiefel Deal
GlaxoSmithKline will more than double its dermatology sales to $1.5 billion with the acquisition of Stiefel Laboratories, a move that provides GSK a foothold in the U.S. market for nonprescription skin-care products